

**INNOTEST PHOSPHO-TAU<sub>(181P)</sub>**Manufactured by:

Fujirebio Europe N.V.  
Technologiepark 6  
9052 Gent  
Belgium  
Tel. +32 9 329 13 29  
BTW BE 0427.550.660  
RPR Gent

Distributed by:

Fujirebio Europe N.V.  
Tel. +32 9 329 13 29  
Fax +32 9 329 19 11  
customer.support@fujirebio-europe.com

Fujirebio Germany GmbH  
Tel. +49 511 857 3931  
Fax +49 511 857 3921  
germany@fujirebio-europe.com

Fujirebio France SARL  
Tel. +33 1 69 07 48 34  
Fax +33 1 69 07 45 00  
france@fujirebio-europe.com

Fujirebio Italia S.r.l.  
Tel. +39 06 965 28 700  
Fax +39 06 965 28 765  
italy@fujirebio-europe.com

Fujirebio Iberia S.L.  
Tel. +34 93 270 53 00  
Fax +34 93 270 53 17  
spain@fujirebio-europe.com

Note changes highlighted

**[www.e-labeling.eu/FRI31928](http://www.e-labeling.eu/FRI31928)****①EUROPE**

GR	+800 135 79 135
IS	00 800 161 220 577 99
LT	800 8996
RO	880 030 728
SK	0800 895 084
TR	0800 606 287
LI	0800 142 064 866
MT	+31 20 796 5692
EE	+31 20 796 5693
	0800 0100 567

**①non-EUROPE**

US	+31 20 794 7071
CA	+1 855 236 0910
AR, BR, CO, UY, AU, NZ, RU	+1 855 805 8539
	+800 135 79 135





8:00 – 17:00 GMT+1

M	T	W	T	F	S	S
☒	☒	☒	☒	☒	☐	☐

## TABLE OF CONTENTS

Symbols used.....	2
Intended use .....	3
Test principle.....	3
Materials provided.....	4
Storage and stability.....	5
Materials required but not provided.....	5
Safety and environment .....	6
Analytical precautions .....	7
Specimen collection, handling and storage (18).....	8
Test procedure .....	9
Control procedure .....	10
Results .....	10
Performance characteristics.....	11
Limitations of the test procedure .....	14
Trademarks.....	14
Literature references .....	14

### Symbols used

	Manufacturer
	<i>In vitro</i> diagnostic medical device
	Batch code
	Catalogue number
	Use by
	Consult Instructions for use
	Temperature limitation
	Contains sufficient for <n> tests
	Conjugate 1 100x
	Conjugate 2 100x
	Conjugate diluent 1
	Conjugate diluent 2
	Microtiter plate
	Sample diluent
	Stop solution
	Substrate TMB 100x
	Substrate buffer
	Wash solution 25x
	Warning
	Enzyme Immunoassay

## Intended use

The INNOTEST PHOSPHO-TAU<sub>(181P)</sub> is a solid-phase enzyme immunoassay for the quantitative determination of phosphorylated Tau (Phospho-Tau<sub>(181P)</sub>) in human cerebrospinal fluid (CSF). In Alzheimer disease (AD) pathology, the phosphorylation of tau protein is disturbed, leading to hyperphosphorylation and the emergence of new sites of phosphorylation. This assay measures specifically the phosphorylation in position 181 threonine.

The combined use of CSF-  $\beta$ -amyloid<sub>(1-42)</sub> and CSF-Tau marker concentrations allows differentiation between AD and normal aging or other neurological diseases such as depression (1). As AD diagnosis marker, the results obtained with this assay should be interpreted in combination with other clinical and diagnostic information (e.g. using results obtained with the INNOTEST hTAU Ag and the INNOTEST  $\beta$ -AMYLOID). The discrimination of AD from non-AD types of dementia such as dementia with Lewy Bodies may be further improved using the quantification of CSF-phospho-Tau<sub>(181P)</sub> (2).

## Background

AD, the most common form of dementia, is a neurodegenerative disorder histologically characterized by the accumulation of intracellular neurofibrillary tangles and extracellular amyloid plaques throughout the cortical and limbic brain regions. The ultrastructure of neurofibrillary tangles is made up of paired helical filaments composed mainly of abnormally hyperphosphorylated Tau protein (Phospho-Tau). The major components of the amyloid deposits are the 40- and 42-amino acid-long  $\beta$ -amyloid peptides, which are derived from integral membrane-bound amyloid precursor protein (3).

## Test principle

The INNOTEST PHOSPHO-TAU<sub>(181P)</sub> is a solid-phase enzyme immunoassay in which the phosphorylated Tau protein or fragments are captured by a first monoclonal human specific antibody, HT7 (IgG1). Human CSF samples are added and incubated with biotinylated AT270 (IgG1) monoclonal. This antigen-antibody complex is then detected by a peroxidase-labeled streptavidin.

After addition of the substrate working solution, samples will develop a color. The color intensity is a measure for the amount of phosphorylated Tau protein in the sample.




Figure 1 Test principle INNOTEST PHOSPHO-TAU<sub>(181P)</sub>; sequence of the synthetic peptide included (SV= streptavidin; HRP= horseradish peroxidase)

**Materials provided**

Reagents supplied:

<b><u>Component</u></b>	<b><u>Quantity</u></b>	<b><u>Ref.</u></b>	<b><u>Description</u></b>
Microtiter plate	1x 96	56625	1 sealed bag containing a strip holder with 12 x 8 coated test wells and a silicagel bag as desiccant.
Sample diluent	1x 30 mL	55706	Phosphate buffer with stabilizing proteins and 0.01% MIT/<0.1% CAA as preservative.
Conjugate 1 100x	1x 0.3 mL	57206	Biotinylated anti-PHOSPHO-TAU <sub>(181P)</sub> (AT270bio) in phosphate buffer with stabilizing proteins and 0.05% Proclin 300 as preservative, to be diluted 100x with conjugate diluent 1 before use.
Conjugate 2 100x	1x 0.3 mL	55528	Peroxidase-labeled streptavidin containing 0.02% MIT and 0.02% bromonitrodioxane as preservative, to be diluted 100x with conjugate diluent 2 before use.
Conjugate diluent 1	1x 20 mL	56627	Color-coded (purple) phosphate buffer with stabilizing proteins and 0.01% MIT/<0.1% CAA as preservative used to dilute conjugate 1.
Conjugate diluent 2	1x 20 mL	55825	Color-coded (green) phosphate buffer containing 0.05% Proclin 300 as preservative used to dilute conjugate 2.
Substrate TMB 100x	1x 0.3 mL	55733	Tetramethyl benzidine (TMB) dissolved in dimethyl sulfoxide (DMSO). Dilute 100x in substrate buffer before use. Concentrated TMB can crystallize and should therefore be melted completely before use (melting point 18°C).
Substrate buffer	1x 30 mL	55727	Phosphate-citrate buffer containing 0.02% hydrogen peroxide, used to dilute the substrate TMB.
Stop solution	1x 30 mL	55523	0.9N sulfuric acid
Wash solution 25x	1x 60 mL	55742	Phosphate buffer containing 0.01% MIT/<0.1% CAA, to be diluted 25x with distilled or deionized water before use. Salt crystals may be formed in the concentrated wash solution after storage at 2-8°C. These crystals should be completely redissolved before dilution.
Plate sealers	4	-	-
Minigrip bag	1	-	For storage of unused strips.

In separate box because of different storage conditions:

Phospho-Tau CAL-RVC pack REF 81575 (to be used with corresponding kit lot number).

<b><u>Component</u></b>	<b><u>Quantity</u></b>	<b><u>Ref.</u></b>	<b><u>Description</u></b>
Ptau	2 x 6 vials		12 CAL vials, containing analyte spiked in diluent.
Calibrators	(0.4 mL)		Use and discard.
Ptau Run	2 x 2 vials		4 RVC vials, containing analyte spiked in artificial
Validation	(0.4 mL)		CSF-like matrix. Use and discard.
Controls			

### **Storage and stability**

- If kept at 2-8°C, and stored in the original vials, the reagents, opened or unopened, are stable until the expiry date of the kit. Do not use the reagents beyond the expiry date.
- After opening the aluminium foil bag containing the strips, any unused test strips will be stable for 16 weeks if stored at 2-8°C in the closed plastic minigrip bag with the silicagel.
- The ready-to-use calibrators (CAL) and Run Validation Controls (RVC) need to be stored at -20°C or lower upon arrival. The CAL and RVC are packed separately from the assay kit.
- Diluted wash solution is stable for 4 weeks if stored at 2-8°C.
- Conjugate working solution 1 and 2 are stable at room temperature for 24 hours.
- Substrate working solution is stable at room temperature for 24 hours if kept in the dark.

### **Description of calibrators**

A set of calibrators in the targeted concentration range of 15.6-1000 pg/mL is provided.

### **Materials required but not provided**

- Distilled or deionized water.
- Calibrated precision pipettes with disposable tip to deliver volumes in the range of 10 – 1000 µL. A calibrated multichannel pipette to deliver 25 µL, 75 µL, and 100 µL is recommended for addition of samples, conjugate working solution 1 and 2, substrate working solution, and stop solution.
- Vortex mixer or equivalent.
- Microplate washer; alternatively, washing can be performed by using a repetitive pipette delivering 400 µL volumes and an aspirating device.
- Timer.
- Absorbent tissues.
- Microplate reader with 450 ± 5 nm filter; optionally, with 620 nm or 690 nm filter for dual wavelength analysis, and with a linear absorbency range of 0 to 3000 or higher.
- Disposable vials for preparation of working solutions (polypropylene BD Falcon tubes recommended).
- Appropriate biohazard waste containers for potentially contaminated materials
- Microplate shaker (1000 rpm); alternatively, mixing can be performed by tapping the side of the plate.
- Incubator at 25 ± 2°C.

## Safety and environment

Please refer to the **Safety Data Sheet (SDS)** and product labelling for information on potentially hazardous components. The most recent SDS version is available on the website [www.fujirebio-europe.com](http://www.fujirebio-europe.com).



### Warning

CONJ	1	100x	CONJ DIL	2
------	---	------	----------	---

Contains mixture of 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-2H-isothiazol-3-one  
H317 P261 P280 P302+P352 P333+P313 P362+P364

SUBS	TMB	100x
------	-----	------

Contains dimethyl sulfoxide  
H315 H319 H335  
P261 P280 P302+P352 P305+P351+P338 P312 P362+P364

### Hazard statements

H315 Causes skin irritation.  
H317 May cause an allergic skin reaction.  
H319 Causes serious eye irritation.  
H335 May cause respiratory irritation.

### Precautionary statements

P261 Avoid breathing mist/vapours/spray.  
P280 Wear protective gloves/protective clothing/eye protection/face protection.  
P302+P352 IF ON SKIN: Wash with plenty of water/...  
P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.  
P312 Call a POISON CENTER or doctor/physician if you feel unwell.  
P333+P313 If skin irritation or rash occurs: Get medical advice/attention.  
P362+P364 Take off contaminated clothing and wash it before reuse.

- Only adequately trained personnel should be permitted to perform the test procedure.
- Specimens should always be handled as potentially infectious. Therefore, all blood components and biological materials should be considered as being potentially infectious and should be handled as such.
- All biological materials should be disposed of in accordance with established safety procedures.
  - Autoclave for at least 15 minutes at 121°C.
  - Incinerate disposable material.
  - Mix liquid waste with sodium hypochlorite so that the final concentration is  $\pm 1\%$  sodium hypochlorite.  
Allow to stand overnight before disposal.  
CAUTION: neutralize liquid waste that contains acid before adding sodium hypochlorite.

REMARK: Special precautions for Transmissible Spongiform Encephalopathy (TSE)/Prion contaminated materials:

- **Inactivation of samples**

Clinical samples, e.g. CSF, should be autoclaved or immersed in a solution of sodium hypochlorite resulting in 20000 ppm free chlorine for 1 hour before final disposal by incineration.

- **Waste disposal**

All material classified as clinical waste should be disposed of by incineration at an authorized incineration site. For the safe handling of clinical waste, use secure leak-proof containers, e.g. double bagging, where appropriate. Avoid external contamination of the container.

- **Reference:**

- Advisory Committee on Dangerous Pathogens (UK) - Spongiform Encephalopathy Advisory Committee - Transmissible Spongiform Encephalopathy Agents: Safe Working and the Prevention of Infection.
- World Health Organization (WHO): WHO Infection Control Guidelines for Transmissible Spongiform Encephalopathies.

See section "Reagents supplied", for information about hazardous substances in the mixtures.

Use of personal protective equipment is necessary: gloves and safety spectacles when manipulating dangerous or infectious agents.

Waste should be handled according to the institution's waste disposal guidelines. All federal, state, and local environmental regulations should also be observed.

**Analytical precautions**

- The following reagents are generic (same composition) between all INNOTEST Abeta(s) and Tau(s) assays: sample diluent, wash solution, substrate, substrate buffer and stop solution. To ensure a correct traceability of used reagents, it is recommended to use a set of these generic reagents from the same box and to record the batch number for each component used.
- All vessels used to prepare conjugate and substrate working solutions must be thoroughly cleaned to avoid contamination.
- Hold the ELISA plates to the sides to avoid contamination of the wells.
- Avoid microbial contamination of the reagents.
- To ensure that samples, RVC, and CAL are homogeneous, vortex them for 10 seconds before use.
- Use a new pipette tip for each specimen.
- Ensure that specimen is added to the microwell.
- Remove any air bubbles by tapping the microtiter plate gently or by mixing on a plate shaker for 1 minute at 1000 rpm.
- Do not expose substrate working solution to strong light during incubation or storage. substrate working solution must be colorless when used. If not colorless, new substrate working solution must be prepared.
- Stop solution, substrate working solution, or conjugate working solutions should not come into contact with metals or metal ions to avoid unwanted color formation.

- If the wells can not be filled with conjugate or substrate working solution immediately after washing, place the strips upside down on an absorbent tissue soaked in wash solution for no longer than 15 minutes.
- Do not use blood collection tubes for the preparation of the reagent working solutions.

### **Specimen collection, handling and storage (18)**

Proper sample handling is very important to obtain accurate results.

Use only **polypropylene** tubes for collection, storage and treatment of the samples (4).

It is recommended to standardize all steps of the sample handling procedure to obtain reproducible results. The assay is not validated for testing post-mortem CSF, ventricular CSF, blood samples (serum, plasma), brain tissue or cell culture supernatants.

#### *CSF collection (5, 6, 7)*

The lumbar puncture should be executed preferably in the morning.

The lumbar puncture should be performed at level L3/L4 or L4/L5.

Discard the 20 first drops of CSF, then collect CSF in a **polypropylene** collection tube. Avoid too much empty space in the tube.

Pretreatment of the samples should be executed preferably within 4 hours after the lumbar puncture.

#### *CSF handling (8)*

Exclude hemorrhagic CSF samples.

Centrifuge CSF 10 minutes at  $\pm 2000g$  at controlled room temperature to exclude cells and other insoluble material.

Aliquot the CSF into polypropylene tubes.

Avoid too much empty space in the tube e.g. preferably dispense 400  $\mu\text{L}$  CSF in a 500  $\mu\text{L}$  tube. Handle the aliquots in line with the shipment conditions.

#### *Shipment to distant testing laboratory*

**Not frozen:** ship the samples within 48 hours at ambient temperature.

**Frozen:** ship the samples on dry ice; avoid thawing of samples.

#### *Storage of CSF aliquots*

Preferably store the samples at  $-80^{\circ}\text{C}$  until testing.

Samples can be stored at  $-20^{\circ}\text{C}$  if tested within 2 months.

Avoid thawing of the samples; repeated freeze/thaw cycles will result in incorrect concentrations (9).

### ***Directions for washing***

For automatic washing, a proposed protocol is as follows:

- Pre-rinse the washer with the diluted wash solution.
- Perform 5 wash cycles ensuring that:
  - the fill volume is 400  $\mu\text{L}$ /well.
  - the dispensing height is set to completely fill the well.
  - the time taken to complete one aspiration/wash/soak cycle is approximately 30 seconds.

- after the washing procedure, the plate is inverted and tapped dry on absorbent tissue.

Manual wash can be performed as follows:

1. Remove the plate sealer.
2. Discard the solution, invert the plate on an absorbent tissue and tap dry.
3. Dispense 400 µL washing solution into each well, soak approximately 30 seconds.
4. Discard the solution, invert the plate on an absorbent tissue and tap dry.
5. Repeat steps 3) and 4) 4 times.

Incomplete washing will adversely affect the test outcome. Contamination of wash solution and washer can cause extensive problems. In case problems occur, disinfect the wash bottles and washer overnight with an appropriate disinfectant solution and rinse with water.

### ***Preparation of the reagents***

#### **Preparation of conjugate working solution 1 and 2 and substrate working solution**

	# wells	8	16	32	64	96
CONJ 1	µL	10	10	15	20	40
CONJ DIL 1	mL	1	1	1.5	2	4
CONJ 2	µL	20	30	40	80	120
CONJ DIL 2	mL	2	3	4	8	12
SUBS	µL	20	30	40	80	120
SUBS BUF	mL	2	3	4	8	12

#### **Preparation of diluted wash solution**

Prepare at least 40 mL of diluted wash solution for each test strip.

	# wells	8	16	32	64	96
WASH SOLN 25x	mL	5	10	20	40	60
H <sub>2</sub> O	mL	120	240	480	960	1440

### **Test procedure**

Please read “Analytical precautions” before performing the test.

NOTE:

- Determine the total number of wells required, considering that for each test run, duplicate wells of the 6 ready-to-use calibrators, 2 Run Validation Controls, and CSF samples should be foreseen.
- Bring the aluminium foil bag containing the strips and all reagents (except the wash solution) to room temperature (18-30°C) and put the wash solution in a warm water bath or incubator at 30-40°C approximately 60 minutes before use. To avoid water condensation into the wells, the aluminium foil bag must be kept closed until the strips have reached room temperature. Return all reagents (inclusive the strips) to the refrigerator immediately after use.
- Allow CAL, RVC, and CSF samples to reach room temperature (18-30°C) approximately 60 minutes before use.
- Make sure that all reagents, CAL, RVC, and CSF samples ready are ready before starting the assay. Once the test has started, it must be performed without any interruption in order to achieve the most reliable and consistent results.

- CSF samples, RVC, and CAL must be vortexed for 10 seconds before testing.
- 1. Take the strip-holder with the required number of strips. Place any unused strip in the plastic minigrip bag with the silicagel desiccant.
- 2. Prepare **conjugate working solution 1** according to the preparations for use.
- 3. Add **25 µL of conjugate working solution 1** to each well of the antibody-coated plate.
- 4. Add **75 µL of each CAL, RVC, and the CSF samples** to duplicate wells of the antibody-coated plate.  
RECOMMENDATION: vortex each sample, RVC, and CAL again for 3 seconds exactly before pipetting them into the plate.
- 5. Make sure that the calibrators, Run Validation Controls, and CSF samples are adequately mixed by carefully tapping the strip-holder or by shaking 1 minute at 1000 rpm. **Cover** the strips with an adhesive sealer. **Incubate** overnight (14-18hrs) in the fridge at 2-8°C.
- 6. Prepare **conjugate working solution 2** -according to the preparations for use- just before the end of step 5.
- 7. **Wash** each well **5 times** (see “Directions for washing”).
- 8. Add **100 µL of conjugate working solution 2** to each well. **Cover** the strips with a new adhesive sealer and **incubate** for 60 ± 3 minutes in an incubator at 25 ± 2°C.
- 9. Prepare **substrate working solution** just before the end of step 8.
- 10. **Wash** each well **5 times** (see “Directions for washing”).
- 11. Add **100 µL of substrate working solution** to each well. **Incubate** for 30 ± 3 minutes at 25 ± 2°C in the dark.
- 12. To stop the reaction, add **50 µL of stop solution** to each well in the same sequence and at the same time intervals as the substrate solution. Tap the strip-holder carefully to ensure optimal mixing.
- 13. **Read** (within 15 minutes after step 12) the absorbance at 450 nm (single wavelength). For dual wavelength analysis, 690 nm or 620 nm can be used as the reference wavelength.

## Control procedure

### *Internal control*

Accredited labs should include an internal control in each run.  
Please follow the applicable quality standard of your accreditation.

## Results

### *Validation*

- The absorbance at 450 nm of CAL 6 should be lower than 0.300.
- The absorbance at 450 nm of CAL 1 should be higher than 1.700.
- The RVC should be within the defined concentration range mentioned on the inserted label of the Phospho-Tau CAL-RVC pack.

### NOTE:

- Absorbance values for dual wavelength (450 nm and 620 nm or 690 nm) analysis differ about 50 mOD from the single wavelength values. This difference does not affect the final outcome of the test.

- RVC concentrations on inserted label are determined using a sigmoidal 4 parameter (no weighting) curve fitting.

### Calculation of results

Calculate the mean absorbance for the CAL, RVC, and the unknown CSF samples. Repeat the test if the % difference  $(\frac{abs(V_1 - V_2)}{((V_1 + V_2)/2)}) * 100$  with  $v = \text{value}$  between individual OD values is more than 20%.

Construct the calibration curve by plotting the mean absorbance values obtained for each of the Phospho-Tau<sub>(181P)</sub> calibrators on the vertical (Y) axis versus the corresponding Phospho-Tau<sub>(181P)</sub> concentrations on the horizontal (X) axis. Draw the best fitting curve through these points.

NOTE: A sigmoidal 4 parameter (no weighting) curve fitting is recommended. If a blank was included in the run, do not use it in the curve fitting.

Use the mean absorbance value of each unknown CSF sample to determine the corresponding concentration of Phospho-Tau<sub>(181P)</sub> in pg/mL from the calibration curve.

The concentration of the samples can only be determined if the absorbance is within the limits of the calibration curve. Extrapolation of results from OD values which are higher than the highest calibrator or lower than the lowest calibrator can lead to incorrect results.

### Performance characteristics

#### Analytical performance characteristics

#### Selectivity and specificity

Details of the isolation and characterization of antibodies HT7 (10) and AT270 (11) have been described. The epitopes of the mAbs were defined with small biotinylated peptides synthesized on pins or used in immunoassay formats. The minimal epitope of mAbs HT7 was defined as P<sub>159</sub>PGQK<sub>163</sub>, while the epitope for AT270 was identified as P<sub>176</sub>PAPKT(p)P<sub>182</sub>. The numbering corresponding to the numbering of the longest Tau isoform (12). All Tau mAbs used in the INNOTEST products have an epitope in the proline-rich region of Tau, as such recognizing in theory all different Tau isoforms (11).




Figure 2 Overview epitopes of Fujirebio Europe antibodies in proline rich region of Tau

Specificity (detection of P-Tau<sub>181P</sub> as opposed to other P-Tau proteins) was evaluated using synthetic biotinylated peptides (sequence Q<sub>165</sub>ANATRIPAKTPPAPKTPPSSGEPKKS<sub>191</sub>) either phosphorylated at Thr181 or non-phosphorylated. The AT270 mAb recognized Tau phosphorylated at threonine 181. No reactivity was obtained using non-phosphorylated peptides or Tau phosphorylated at other sites (12). No cross-reactivity with recombinant Tau was obtained in quantified CSF in concentration ranges corresponding to healthy and affected individuals.

### **Analytical sensitivity**

A blank sample (= sample diluent) was tested in 16-fold over different runs to determine the Limit of Detection (LoD). The mean + 2\*Standard Deviation (SD) of the blank sample's reactivity level was calculated and subsequently converted, via the inverse sigmoid relation, into a concentration. The obtained LoD was 13 pg/mL.

### **Assay range**

The assay range is determined by the Lower Limit of Quantitation (LLoQ) and the Upper Limit of Quantitation (ULoQ), which is defined as the lower and upper points where the precision and the estimated bias does not exceed 20%. A total of 16 CSF samples and 2 RVC samples were tested by 4 operators over different days and in duplicate (2 reported values). The obtained assay range using this sample set is 20 pg/mL (LLoQ) (i.e. the CSF with the lowest concentration) to 199 pg/mL (ULoQ) (i.e. the RVC1 sample, sample evaluated with highest concentration).

### **Accuracy**

At present, the accuracy for detection of the AD biomarkers is difficult to investigate since no reference material (internationally recognized gold standard) is currently available. Proteins from different sources can vary in their immunoreactivity due to the production and/or purification processes. In addition, the reference material may not be truly representative for the native protein due to differences in post-translational modifications (e.g. phosphorylation, dimerization, glycosylation, deamidation, isomerization). No standard has currently been deposited with any organization, such as the World Health Organization (WHO) or United States Pharmacopoeia (USP).

### **Precision**

Precision (intra-assay and inter-assay variability) was evaluated. A total of 16 CSF samples, 2 RVC and 6 RTU calibrators were tested by 4 operators over different days, and in duplicate (2 reported values). The precision of the CSF samples and the RVC samples is presented in Table 1.

*Table 1: Overview of precision on CSF and RVC samples*

	CSF samples (n=16)	RVC 1 (high concentration)	RVC 2 (low concentration)
Intra-assay variation	1.7% (range 0.0% - 8.9%)	3.3% (range 2.1% - 3.9%)	2.8% (range 0.7% - 4.5%)
Inter-assay variation	11.4% (range 6.6% - 19.2%)	6.9% n.a.	5.2% n.a.

The variability on the 6 RTU calibrators is schematically represented in a precision profile (Figure 3). The individual reactivity levels of 40 RTU calibration curves were analyzed towards their average calibration curve. The variability over their back calculated concentrations for each of the calibrators was determined.

The % CV (combined inter- and intra-assay variation) at each level of RTU calibrators does not exceed 15% except for the highest calibrator point (= anchor point).

	conc. (pg/mL)	%CV
CAL 1	936	>25%
CAL 2	247	14.8
CAL 3	113	8.8
CAL 4	59.9	8.0
CAL 5	31.8	13.1
CAL 6	15.6	10.4




Figure 3 Variability in function of the defined calibrator concentration. Average reactivity levels of the calibrators are plotted against the left Y axis, % CV values are plotted against the right Y axis. CAL1 is not present on the figure (% CV > 25%).

### ***Biological reference interval***

An external study (15) was conducted with INNOTEST Phospho-Tau<sub>(181P)</sub>, in which biological reference intervals were derived from 129 neurologically and psychiatrically healthy individuals.

Following references values have been determined (median followed by 25%-75% percentile between brackets), partitioned according to age:

<u>Age</u>	<u>CSF Phospho-Tau<sub>(181P)</sub> (pg/mL)</u>
18-44 years	29.58 (19.66-45.67)
45-77 years	46.66 (35.84-66.26)

Note that it is strongly advised that each laboratory assesses the acceptability of the transference of a reference interval obtained in another laboratory; the reference intervals provided above should only be considered as guidance values to start the in-house validation.

## **Clinical results**

An external validation multicenter study was performed (2) to determine PHOSPHO-Tau<sub>(181P)</sub> concentrations in stored CSF samples of 76 patients with Alzheimer's disease (AD), 53 control subjects (CS) and 52 patients with dementia with Lewy bodies (DLB). PHOSPHO-Tau<sub>(181P)</sub> concentrations were significantly increased in the AD-group as compared to the CS-group and the DLB-group. At a cut-off of 61 pg/mL, the following results were obtained:

AD vs CS: Specificity = 87% Sensitivity = 80%

AD vs DLB: Specificity = 79% Sensitivity = 80%

These results confirm the discriminatory value of the assay as found in a first internal evaluation (13).

The value of  $\beta$ -amyloid<sub>(1-42)</sub>, Tau protein and CSF-phospho-Tau181 has been demonstrated in autopsy-confirmed dementia cases, achieving sensitivity, specificity and diagnostic accuracy levels, consistently exceeding 80% (14).

## **Limitations of the test procedure**

The INNOTEST PHOSPHO-TAU<sub>(181P)</sub> assay procedure was designed to quantify PHOSPHO-TAU<sub>(181P)</sub> in human cerebrospinal fluid. Insufficient data are available to interpret tests performed on other body fluids or brain tissue samples. Testing of such samples is therefore not recommended.

The possible use of the assay for therapy monitoring will largely depend on the type of therapy, which could interfere with the assay design.

## **Trademarks**

- **INNOTEST** is a trademark of Fujirebio Europe N.V., registered in US and other countries.
- BD Falcon is a trademark of Becton, Dickinson and Company.

## **Literature references**

1. Hulstaert et al.  
Improved discrimination of AD patients using beta-amyloid<sub>(1-42)</sub> and Tau levels in CSF. *Neurology* 1999 12;52:1555-62
2. Vanderstichele et al.  
Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU<sub>(181P)</sub> assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. *Clin Chem Lab Med.*2006;44:1472-80
3. Ballatore C, Lee V M-Y, Trojanowski JK.  
Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. *Nat Rev Neurosci* 2007; 8:663-672
4. Andreasen et al.  
Cerebrospinal fluid beta-amyloid<sub>(1-42)</sub> in Alzheimer's disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. *Arch Neurol.* 1999;56:673-80
5. Peskind et al.  
Safety of lumbar puncture procedures in patients with Alzheimer's disease. *Curr Alzheimer Res.* 2009;6:290-2

6. Peskind et al.  
Cerebrospinal fluid: when is it worthwhile to do a lumbar puncture? *CNS Spectr.* 2008;13:25-7
7. Peskind et al.  
Safety and acceptability of the research lumbar puncture. *Alzheimer Dis Assoc Disord.* 2005;19:220-5
8. Schoonenboom et al.  
Effects of processing and storage conditions on amyloid beta<sub>(1-42)</sub> and Tau concentrations in cerebrospinal fluid: implications for use in clinical practice. *Clin Chem.* 2005;51:189-95
9. Vanderstichele et al.  
Standardization of measurement of  $\beta$ -amyloid<sub>(1-42)</sub> in cerebrospinal fluid and plasma. *Amyloid: Int J Exp Clin Invest* 2000; 7: 245-258
10. Mercken et al.  
Immunocytochemical detection of the growth-associated protein B-50 by newly characterized monoclonal antibodies in human brain and muscle. *J Neurobiol* 1992;23:309-321
11. Goedert et al.  
Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. *Biochem J* 1994;301:871-877
12. Vanmechelen et al.  
Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. *Neurosci Lett.*2000;285(1):49-52
13. Vanmechelen et al.  
CSF-Phospho-Tau<sub>(181P)</sub> as a promising marker for discriminating Alzheimer's disease from dementia with Lewy bodies In: *Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics.* Edited by K Iqbal, SS Sisodia and B. Winblad, John Wiley and Sons, Ltd., Chichester, 2001: 285-291
14. Engelborghs et al.  
Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. *Neurobiol Aging.* 2008;29:1143-59
15. Jaworski et al.  
Total-tau and phospho-tau(181Thr) in cerebrospinal fluid of neurologically intact population increase with age. *Folia Biol (Praha).* 2009;55:126-31
16. Vanderstichele et al.  
Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. *Alzheimer's & Dementia* 8 (2012);65-73